$OSRH

OSR Health, Inc. (OSRH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 OSR Health Provides Shareholder Update Following Nasdaq Panel Decision Company evaluating options to regain compliance; further update expected by November 6, 2026; $15 million VXM01 funding mechanism remains in place; committed to continuing Shareholder Loyalty Prog

OSR Health (OTC PINK:OSRH) announced its delisting from Nasdaq due to non-compliance. The company chose not to pursue a reverse stock split and plans to regain compliance through organic initiatives. OSR Health is evaluating options to return to a national exchange and will update shareholders by November 6. The company continues its Shareholder Loyalty CVR Program and pipeline development, including VXM01, Darnatein's programs, and Woori IO's technology.

OSR Health amended its VXM01 license agreement with BCM Europe, adding a $15 million convertible note option in four tranches. The move follows a Nasdaq delisting and aims to preserve financing flexibility. Conversion prices range from $2 to $5 per share, with no resets. The amendment is effective from October 15, 2026.

OSR Health, Inc. (OSRH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, OSR Health, Inc. (the “Company”), its wholly owned subsidiary Vaximm AG, and BCM Europe AG (“BCME”) are parties to a Global Exclusive License Agreement for VXM01, effective April 29, 2026 (the “Licens

OSR Health, Inc. (OSRH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, Dr. Constance Hoefer provided notice of her resignation as Chief Scientific Officer of OSR Health,

Emerging Growth Research released a company-sponsored flash report on OSR Health, Inc. (OSRH), highlighting its Shareholder Loyalty Program with tiered rewards based on stock price milestones. The program aims to reward long-term shareholders and improve liquidity. OSRH recently secured an $815 million licensing deal for drug candidate VXM01. EGR notes growth drivers and risks, including dilution and potential short-selling pressure. OSRH shares trade on NASDAQ.

OSR Health, Inc. (NASDAQ:OSRH) announced plans to appeal its Nasdaq delisting, with a hearing request due by August 26. The company also highlighted a $15 million Put Option with BCM Europe AG, exercisable at $10.00 per share from October 29, 2026, and continued development of its subsidiaries' pipelines. The CEO emphasized the Put Option's significance and the company's resilience despite current challenges.

OSR Health, Inc. (NASDAQ:OSRH) received a Nasdaq staff delisting determination for failing to meet the minimum bid price requirement. The company plans to appeal, citing recent trading activity and business fundamentals. On August 17 and 18, 2026, OSRH traded 370 million and 145 million shares respectively, with a public float of 18.5 million shares.

OSR Health, Inc. (OSRH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders On August 7, 2026, the Company held an annual meeting of its stockholders (the “ Annual Meeting ”). As of the close of business on July 8, 2026, the record date for the Annual Meeting, there were 35,118,692 shares of

OSR Health, Inc. (NASDAQ:OSRH) clarified a July 31, 2026 press release about Nasdaq and its Shareholder Loyalty CVR Program. The company said Nasdaq’s earlier communication was only a preliminary, verbal technical indication about whether the program would mechanically adjust OSRH’s stock price, not approval or endorsement. The August 14, 2026 record date remains unchanged.